ライフサイエンスコーパス: new oral anticoagulant

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 causes including antiplatelet agents and the new oral anticoagulants.

2 New oral anticoagulant agents are effective and safe alt

3 Further clinical research is required before new oral anticoagulant agents can be considered standard

4 suspected PE, and the efficacy and safety of new oral anticoagulant agents in patients with cancer.

5 New oral anticoagulants also significantly reduced all-c

6 42,411 participants received a new oral anticoagulant and 29,272 participants received

7 Although new oral anticoagulants appear promising, clinical trial

8 New oral anticoagulant approval may provide safer and ea

9 New oral anticoagulants are a viable option for patients

10 New oral anticoagulants are effective for thromboprophyl

11 Overall, the new oral anticoagulants are poised to replace vitamin K

12 inicians a more comprehensive picture of the new oral anticoagulants as a therapeutic option to reduc

13 Experience with new oral anticoagulants as acute, long-term, and extende

14 Four new oral anticoagulants compare favourably with warfarin

15 The new oral anticoagulants dabigatran and rivaroxaban have

16 mitations of aspirin and the availability of new oral anticoagulant drugs that overcome the inherent

17 New oral anticoagulants for stroke prevention in atrial

18 views the latest evidence and development of new oral anticoagulants for the prevention of ischaemic

19 New oral anticoagulants, for example, offer cost-effecti

20 Development of new oral anticoagulants further simplifies acute-phase t

21 New oral anticoagulants had a favourable risk-benefit pr

22 New oral anticoagulants have not been compared with warf

23 We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effect

24 sults from Phase II/III studies suggest that new oral anticoagulants may provide an efficacious alter

25 observed in patients with AF randomized to a new oral anticoagulant (NOAC) who transitioned to a vita

26 New oral anticoagulants (NOACs), including direct thromb

27 New oral anticoagulants (NOACs), including direct thromb

28 The new oral anticoagulants (NOACs), which include dabigatra

29 Data for warfarin compared against the new oral anticoagulants (OACs) in large phase III clinic

30 fibrillation who were randomised to receive new oral anticoagulants or warfarin, and trials in which

31 Low-dose new oral anticoagulant regimens showed similar overall r

32 The new oral anticoagulants should increase the number of pa

33 and effective for treating thrombosis, these new oral anticoagulants should next be studied for treat

34 New oral anticoagulants significantly reduced stroke or

35 New oral anticoagulants, statins and concomitant therapy

36 is is the first to include data for all four new oral anticoagulants studied in the pivotal phase 3 c

37 New oral anticoagulants (such as dabigatran, rivaroxaban

38 New oral anticoagulants, such as factor IIa and factor X

39 imitations that prompted the introduction of new oral anticoagulants targeting the single coagulation

40 r Xa inhibitors rivaroxaban and apixaban are new oral anticoagulants that are at least as efficacious

41 Dabigatran and rivaroxaban are new oral anticoagulants that are eliminated through the

42 ergo a major change with the introduction of new oral anticoagulants that are likely to fulfill many

43 limitations have prompted the development of new oral anticoagulants that target either factor Xa or

44 Dabigatran etexilate was the first new oral anticoagulant to be approved for long-term anti

45 The relative efficacy and safety of new oral anticoagulants was consistent across a wide ran

46 er relative reduction in major bleeding with new oral anticoagulants when the centre-based time in th

47 standard'' for a dose administration of the new oral anticoagulant, where the Deltaf/DeltaGamma rati

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。